COMPLETE RESEARCH GUIDEMEDIT PEN
MediT Pen
Tirzepatide 40mg — Metabolic Research Pen
>99%40 mgFROM EUR 249NEW
QUICK ANSWER
MediT Pen (tirzepatide 40mg — metabolic research pen) is a >99% purity research compound. The ORYN MediT Pen is a prefilled, single-use injection pen containing 40mg Tirzepatide (>99% purity). Designed for once-weekly administration in metabolic research protocols, it features dual GIP/GLP-1 receptor agonism — the most studied dual incretin compound in clinical trials.. ORYN delivers MediT Pen in a prefilled single-use pen starting from EUR 249. All products are for research purposes only.
Science & Research
FULL ENCYCLOPEDIA ENTRY →MOLECULAR PROFILE
FORMULA
C225H348N48O68
WEIGHT
4813.45 Da
CLASSIFICATION
Dual GIP/GLP-1 Receptor Agonist (Incretin Mimetic)
STUDIES CITED
4 key studies
Mechanism of Action
Tirzepatide represents a paradigm shift in metabolic peptide science as the first dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist. By activating both incretin pathways simultaneously, it produces metabolic effects that exceed what either pathway achieves alone.
READ FULL MECHANISM →Key Published Studies
2021
SURPASS-2: Tirzepatide versus semaglutide in patients with type 2 diabetes
Tirzepatide demonstrated superior HbA1c reduction vs. semaglutide 1mg, with significantly greater weight loss at all three dose levels.
2022
SURMOUNT-1: Tirzepatide for treatment of obesity
72-week treatment achieved 22.5% mean weight reduction at the 15mg dose in participants with obesity, the highest ever recorded for a pharmaceutical agent.
2020
Dual GIP/GLP-1 receptor agonism: mechanisms and metabolic effects
Characterised the synergistic metabolic benefits of dual incretin activation, including enhanced insulin sensitivity, fat metabolism, and appetite regulation.
2023
SURMOUNT-4: Sustained weight loss maintenance with tirzepatide
Demonstrated that continued tirzepatide treatment maintained weight loss over 88 weeks, while discontinuation led to significant regain, underscoring the importance of sustained treatment.
Research History
Tirzepatide was developed by Eli Lilly and Company, building on decades of incretin biology research. The concept of dual incretin receptor agonism emerged from observations that GIP and GLP-1 activate complementary metabolic pathways, and that simultaneous activation might produce synergistic benefits.
FULL RESEARCH HISTORY →ORYN MediT Pen Product
MEDIT PENNEW
MediT Pen — Tirzepatide 40mg — Metabolic Research Pen
The ORYN MediT Pen is a prefilled, single-use injection pen containing 40mg Tirzepatide (>99% purity). Designed for once-weekly administration in metabolic research protocols, it features dual GIP/GLP-1 receptor agonism — the most studied dual incretin compound in clinical trials.
PURITY
>99%
TYPE
Prefilled Injection Pen
DOSAGE
40 mg Tirzepatide
FREQUENCY
Once Weekly
RESEARCH APPLICATION
Metabolic and incretin pathway studies
MECHANISM
Dual GIP/GLP-1 Agonist
EUR 249VIEW PRODUCT DETAILS
Articles & Guides
ALL ARTICLES →LEGAL & COMPLIANCE
Are Peptides Legal in the UK? Complete 2026 Guide
Understanding the legal landscape of research peptides in the United Kingdom. What you need to know about purchasing, possessing, and using peptides in 2026.
8 min read
PEPTIDE RESEARCH
Tirzepatide vs Semaglutide: Comparing Weight Loss Peptides
A comprehensive comparison of two leading metabolic peptides — tirzepatide's dual GIP/GLP-1 action versus semaglutide's GLP-1 approach.
7 min read
PEPTIDE RESEARCH
Best Peptides for Weight Loss in the UK (2026)
A comprehensive guide to the leading metabolic and weight-loss peptides available for research in the UK. Compare mechanisms, efficacy data, and delivery systems.
9 min read
BUYING GUIDES
Best Peptide Pens UK 2026: Complete Buyer's Guide
A comprehensive comparison of the best peptide pen systems available in the UK market for 2026, including ORYN, PharmaLabGlobal, and other leading suppliers.
12 min read
BUYING GUIDES
How to Buy Peptides Online in the UK: 2026 Definitive Guide
Your complete guide to safely purchasing research peptides online in the UK, including how to verify quality, spot scams, and choose the right supplier.
9 min read
PRODUCT GUIDES
Tirzepatide Pen UK: Complete Research Guide 2026
Everything UK researchers need to know about tirzepatide peptide pens: mechanism of action, dosing, ORYN's dual pen options, and how it compares to semaglutide.
10 min read
Head-to-Head Comparisons
ALL COMPARISONS →COMPARISON
Tirzepatide vs Semaglutide: Which Weight Loss Peptide Is Superior?
TirzepatideVSMediT Pen
Clinical data consistently shows tirzepatide's dual GIP/GLP-1 mechanism produces greater weight reduction than semaglutide's GLP-1-only approach. ORYN offers tirzepatide in two formats: the standard pen (10mg, €169) and the MediT prefilled pen (40mg, €249).
COMPARISON
Tirzepatide 10mg Pen vs 40mg MediT: Which Format Is Right?
TirzepatideVSMediT Pen
Both formats deliver the same pharmaceutical-grade tirzepatide with >99% purity. The Tirzepatide Pen (10mg, €169) offers maximum dosing flexibility for titration and dose-finding research. The MediT Pen (40mg, €249) offers maximum convenience with once-weekly fixed-dose administration. Your choice depends on whether flexibility or simplicity is more important for your research protocol.
COMPARISON
Ipamorelin vs Tirzepatide: Growth Hormone vs Metabolic Peptide
IpamorelinVSTirzepatide
Ipamorelin and Tirzepatide are entirely different classes of peptide. Ipamorelin is a selective growth hormone secretagogue — ideal for research into GH-mediated effects like body composition, sleep, and recovery. Tirzepatide is a dual GIP/GLP-1 receptor agonist — the leading compound for metabolic and weight management research. The choice depends entirely on your research focus: growth hormone biology or metabolic science.
COMPARISON
CJC-1295 vs Semaglutide: Growth Hormone vs Weight Loss Peptide
CJC-1295VSTirzepatide
CJC-1295 and Semaglutide (compared here alongside Tirzepatide) serve entirely different purposes. CJC-1295 is a GHRH analogue for sustained growth hormone research — body composition, recovery, sleep, and anti-ageing. Semaglutide and Tirzepatide are incretin-based compounds for metabolic and weight management research. ORYN offers CJC-1295 for GH protocols and Tirzepatide (which surpasses Semaglutide in clinical data) for metabolic protocols.
COMPARISON
Peptide Pen vs MediT Pen: Multi-Dose Daily vs Prefilled Weekly
TirzepatideVSMediT Pen
The Peptide Pen and MediT Pen represent two distinct delivery philosophies. The Peptide Pen system offers maximum dosing flexibility with daily precision control across 8 peptide compounds. The MediT Pen offers maximum convenience with prefilled, once-weekly dosing. Both use pharmaceutical-grade compounds with >99% purity — the choice comes down to whether your protocol benefits more from flexibility or simplicity.
COMPARISON
MediT Pen vs NovaDose: Weekly Injection vs Daily Cartridge System
MediT PenVSNovaDose NAD+
The MediT Pen and NovaDose represent ORYN's two advanced delivery platforms, each optimised for different compounds and dosing philosophies. The MediT Pen delivers Tirzepatide in a prefilled weekly format — maximum convenience for metabolic research. The NovaDose delivers NAD+ via an advanced cartridge system for daily microdosing — maximum precision for cellular energy research. They are complementary systems serving different research needs.
COMPARISON
Tirzepatide vs CJC-1295 for Weight Management: Which Approach Works?
TirzepatideVSCJC-1295
For direct weight management research, Tirzepatide is overwhelmingly superior — clinical trials show 15-21% body weight reduction through dual GIP/GLP-1 receptor action. CJC-1295 supports body composition indirectly through sustained GH release, improving lean mass and fat metabolism. They represent fundamentally different approaches: Tirzepatide reduces weight through appetite and metabolic regulation, whilst CJC-1295 improves body composition through anabolic GH pathways.
COMPARISON
Tirzepatide vs NAD+: Two Approaches to Metabolic Research
TirzepatideVSNAD+
Tirzepatide and NAD+ address metabolism through entirely different mechanisms. Tirzepatide acts on incretin receptors (GIP/GLP-1) to regulate appetite, insulin sensitivity, and body composition. NAD+ restores mitochondrial energy production and activates sirtuin longevity pathways. Tirzepatide is the stronger choice for weight and glycaemic research; NAD+ is superior for cellular energy and systemic aging endpoints.
COMPARISON
MediT Pen vs Standard Tirzepatide Pen: Which Format Fits Your Research?
MediT PenVSTirzepatide
The MediT prefilled pen (40 mg, EUR 249) offers maximum convenience with weekly dosing and 4x more tirzepatide per unit. The standard pen (10 mg, EUR 169) offers maximum flexibility with adjustable daily dosing. The MediT is better value per milligram (EUR 6.23/mg vs EUR 16.90/mg) and ideal for established protocols. The standard pen is ideal for dose-finding research or researchers who need precise daily adjustments.
Research Protocols
ALL PROTOCOLS →Frequently Asked Questions
FULL FAQ →What is tirzepatide and how is it different from semaglutide?
+
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both major incretin pathways simultaneously. Semaglutide is a GLP-1 receptor agonist only. Clinical trials show tirzepatide achieves greater weight loss (up to 22.5%) and superior glycaemic control compared to semaglutide, likely due to the synergistic effects of dual receptor activation.
What is the mechanism of action of tirzepatide?
+
Tirzepatide activates GIP and GLP-1 receptors simultaneously. GLP-1 pathway activation slows gastric emptying, reduces appetite, and enhances insulin release. GIP pathway activation improves insulin sensitivity in fat tissue and promotes fat metabolism. The combined effect produces metabolic benefits exceeding either pathway alone.
What clinical evidence supports tirzepatide?
+
The SURPASS trials demonstrated tirzepatide's superiority over semaglutide for diabetes management. The SURMOUNT trials showed 22.5% mean weight reduction at 15mg — the largest pharmacological weight loss ever recorded. Tirzepatide is FDA-approved as Mounjaro (diabetes) and Zepbound (obesity).
How does ORYN deliver tirzepatide?
+
ORYN offers two tirzepatide delivery systems: the Peptide Pen (10mg, 30-day precision dosing) and the MediT Pen (40mg prefilled, once-weekly single-use injection). Both are >99% purity and GMP manufactured. The MediT Pen is designed for convenience with pre-set weekly dosing.
What is the MediT Pen?
+
The MediT Pen is ORYN's prefilled, single-use injection pen containing 40 mg of Tirzepatide. It is designed for once-weekly subcutaneous administration, providing a full dose in a single injection. The prefilled format eliminates any dosing calculation or reconstitution, making it the most convenient Tirzepatide delivery system available for research.
How does the MediT Pen differ from the standard Tirzepatide Pen?
+
The standard ORYN Tirzepatide Peptide Pen contains 10 mg and is designed for daily dosing over 30 days. The MediT Pen contains 40 mg in a prefilled, single-use format for once-weekly injection. The MediT Pen delivers a higher per-dose concentration and is suited to weekly dosing research protocols, while the standard pen suits daily micro-dosing protocols.
How is the MediT Pen administered?
+
The MediT Pen is administered as a once-weekly subcutaneous injection. Simply remove the cap, prime the pen if required, select the injection site (typically the abdomen, thigh, or upper arm), and inject. The prefilled design means no reconstitution, no dose dialling, and no multi-step preparation.
What purity is the MediT Pen Tirzepatide?
+
The MediT Pen contains Tirzepatide manufactured to >99% purity under GMP-certified conditions. Each production batch is independently tested via HPLC and mass spectrometry. Certificates of Analysis are available for verification.
Explore More ORYN Products
RESEARCH PURPOSES ONLY. All content on this page is intended for informational and educational purposes for qualified researchers. ORYN products are not approved as medicines and are not intended for human therapeutic use. Do not use ORYN products for self-administration. Consult relevant regulations in your jurisdiction.